Literature DB >> 33906909

Novel Therapeutic Options for Cardiovascular Disease with CKD.

Carmine Zoccali1, Francesca Mallamaci2.   

Abstract

Entities:  

Keywords:  apabetalone; cardiovascular disease; chronic kidney disease; epigenetic modifiers; heart failure; mortality risk

Mesh：

Year:  2021        PMID： 33906909      PMCID： PMC8259479          DOI： 10.2215/CJN.03270321

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

Review 1.  CKD and poverty: a growing global challenge.

Authors:  Mohammed P Hossain; Elizabeth C Goyder; Jan E Rigby; Meguid El Nahas
Journal:  Am J Kidney Dis       Date:  2009-01       Impact factor: 8.860

Review 2.  Epigenetic memory of environmental organisms: a reflection of lifetime stressor exposures.

Authors:  Leda Mirbahai; James K Chipman
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2013-10-17       Impact factor: 2.873

3.  A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

Authors:  Ravi Jahagirdar; Haiyan Zhang; Salman Azhar; Jennifer Tobin; Sarah Attwell; Raymond Yu; Jin Wu; Kevin G McLure; Henrik C Hansen; Gregory S Wagner; Peter R Young; Rai Ajit K Srivastava; Norman C W Wong; Jan Johansson
Journal:  Atherosclerosis       Date:  2014-06-28       Impact factor: 5.162

4.  Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.

Authors:  Kausik K Ray; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Peter P Toth; Norman Wong; Michael Sweeney; Gregory G Schwartz
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

5.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.

Authors:  Aruna D Pradhan; Aaron W Aday; Lynda M Rose; Paul M Ridker
Journal:  Circulation       Date:  2018-05-01       Impact factor: 29.690

6.  Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Authors:  Edward P Havranek; Mahasin S Mujahid; Donald A Barr; Irene V Blair; Meryl S Cohen; Salvador Cruz-Flores; George Davey-Smith; Cheryl R Dennison-Himmelfarb; Michael S Lauer; Debra W Lockwood; Milagros Rosal; Clyde W Yancy
Journal:  Circulation       Date:  2015-08-03       Impact factor: 29.690

Review 7.  Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Dimitris Mavridis; Eliano Navarese; Jonathan C Craig; Marcello Tonelli; Georgia Salanti; Natasha Wiebe; Marinella Ruospo; David C Wheeler; Giovanni F M Strippoli
Journal:  Lancet       Date:  2015-05-23       Impact factor: 79.321

8.  Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.

Authors:  Kamyar Kalantar-Zadeh; Gregory G Schwartz; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Ewelina Kulikowski; Kenneth Lebioda; Peter P Toth; Norman Wong; Michael Sweeney; Kausik K Ray
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-27       Impact factor: 8.237

9.  Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.

Authors:  Dario Giugliano; Luca De Nicola; Maria Ida Maiorino; Giuseppe Bellastella; Carlo Garofalo; Paolo Chiodini; Antonio Ceriello; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2020-03-19       Impact factor: 9.951
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.